Vanguard Global Advisers
ATNM icon

Vanguard Global Advisers’s Actinium Pharmaceuticals ATNM Stock Holding History

Vanguard Global Advisers’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.71K Hold
8,893
– – ﹤0.01% 3496
2026
Q1 		$8.85K Buy
+8,893
New +$10.6K ﹤0.01% 3491

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's ATNM Position: Q2 2026 in Review

Vanguard Global Advisers held its Actinium Pharmaceuticals (ATNM) position steady in Q2 2026 at 8,893 shares worth $8.71K. The position accounts for ﹤0.01% of the portfolio, ranked #3496.

Vanguard Global Advisers first reported a position in ATNM in Q1 2026 and has held it in 2 quarters since. The position peaked at $8.85K in Q1 2026. 46 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Vanguard Global Advisers held 8,893 shares of Actinium Pharmaceuticals worth $8.71K as of Q2 2026.
  • Vanguard Global Advisers left its Actinium Pharmaceuticals share count unchanged in Q2 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3496 holding.
  • Vanguard Global Advisers first reported a position in Actinium Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Actinium Pharmaceuticals position peaked at $8.85K in Q1 2026.
  • 46 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.